|
The Parkinson’s Action Network
participated in a Food and Drug Administration (FDA) hosted conference on
November 6-7 entitled “Assessing Drug Benefits and Risks in Regulatory
Decisions: Framing the Need, Evaluating the Tools, and Deciding Next Steps,” in
Silver Spring, Md. The conference attendees were
primarily FDA regulators and representatives from the pharmaceutical and
biotech industries.
PAN California Congressional Coordinator, Greg
Wasson, J.D., who has been a grassroots advocacy leader at PAN for over a
decade addressed the conference on the first day. In addition to
participation on a panel, Greg gave sophisticated remarks on patient involvement
in benefit-risk decisions and the need for enhanced decision making tools in
the 21st century.
The following
are his remarks: Good Afternoon. Thank you for
inviting me to speak as a patient advocate at this meeting. Because I have a
currently incurable, progressive degenerative brain disease, I am going to finally
heed the advice of my neurologist and read from text for this talk. I should
start by telling you a little bit about myself.
While in many ways I am increasingly the typical 21st century
patient sitting in the doctor’s waiting room or standing in line at the
pharmacy, in other significant ways I am an atypical patient. The differences
between the two may present the biggest challenges to creating effective
decision-making tools for patients if we are serious about giving patients as a
class a meaningful seat at the health care policy table, and real power as
individual patients to make, or meaningfully participate in, decisions in the
management of their own health care.
I am a typical 21st
Century patient in the following ways: I am middle-aged. I have chronic
co-morbidities, including Parkinson’s disease for (which I’ve had for 12 years),
type II diabetes, and hypertension. I passed by my ideal weight 20 pounds and
20 years ago. I take nine different
prescription medications multiple times daily to help manage my diseases and
their symptoms. As I am speaking, there is a small device behind and inside my
left ear, which feeds an altered and minutely delayed reproduction of what I
have just said into the auditory and speech channels in my brain (I also hear
it consciously – it sounds a little like Mickey Mouse on helium), which makes
it possible for me to speak at sufficient volume and with enough clarity to be
understood despite the speech degeneration caused by my Parkinson’s.
Increasingly, such complex combinations of illnesses and their symptoms and
possible treatments are becoming typical of the kind of matrix that patients,
doctors, and the health care system generally will have to deal with as we move
from a system built on acute care to one focusing on the care management of an
older population with multiple chronic health problems.
I am also an atypical patient. I
was a lawyer and a book editor, which places me above the mean in
education. Both my profession and education
have given me skills that help with problem solving, locating and synthesizing information, and working my way through texts that
frequently include words and terms that are new to me. I have been a Parkinson’s disease advocate
for a decade, which has familiarized me with the current systems and networks
for the provision and regulation of health care beyond even the average
well-educated lay person. I use the Internet and know how to search for information relevant to my health care. English is my
native language. Lastly, I am a white male, which gives me less quantifiable
but important cultural and social affinities with most health care professionals.
This conference has included
patients as stakeholders and decision-makers in the management of their own
health care and its regulation. The Parkinson’s Action Network (PAN) applauds
this as an example of the FDA’s response to the general criticism that the
missing voice at the healthcare policy table is the voice of the patient. I
think it is vital that the patient voice be included not only in individual
health care decisions, but at every level of decision making, including IRB’s,
Advisory Committees to PhARMA and Biotech companies, and relevant government
agencies. Patient participation in health
care decisions still has a long way to go before it is an accepted fact and not
just a platitude, but thankfully we are making a start.
For the patient to participate as a
full-fledged stakeholder in today’s health care environment, we must overcome a
health care culture stretching back generations. This culture has regarded the patient as a
passive and uninformed recipient of
the specialized knowledge and training possessed in some measure by everyone
else here today. A patient’s unsolicited input or questions about diagnoses or
treatment protocols have traditionally been met with an attitude of “you worry
about your insurance (or lack of it), and I’ll worry about how to treat you.” More often than not, patients accepted and
even encouraged the assumption that doctors, researchers, drug companies, and
government regulators were responsible for and capable of fixing what ailed
them. It was comforting to think that
the people in the labs coats—one part scientist, one part magician--had
solutions to all of our medical problems. Gradually, however, more and more patients
have been disabused of that comforting but erroneous notion.
The idealization of medicine hasn’t
completely disappeared, but two factors are hastening its demise. First, physicians increasingly have less time
to spend with each patient, reducing both the time that the physician has to
get a clear picture of the particular patient and the problems he or she
presents, and to give the patient a clear understanding of a chosen or proposed
treatment. Secondly, we now have an
active patient population that increasingly wants and needs to have a voice in
the decisions made about its health care. That population--particularly the growing
number with chronic illnesses like Parkinson’s that require a lifetime of
treatment decisions as the disease progresses--needs tools to assess risk and
benefit in managing their care.
That said, all of us here today,
including patients and their representatives, must recognize that the average
patient, while integral to the processes of both individualized health
decisions and the broader area of healthcare policymaking, is unlikely to have
specialized training in medicine, pharmacology, biologics, the systems and
organizations that provide healthcare, healthcare policy language, or the Code
of Federal Regulations. We run a great
risk in simply handing over to individual patients an array of treatment
options to choose from as if they were a smorgasbord without also providing the
tools that they need to make informed
decisions. Likewise, we must create
tools by which the unique perspective, which only patients can give as to the
experience of their illness and its treatment can be captured and used to
better inform the policymaking
process. Creating these tools will not be simple or easy, but create them we
must if we are to make the once passive recipients of health care decisions
made by others into effective and meaningful collaborators in developing healthcare
policies and practices which will meet the new requirements of a new century.
With regard to decision-making at
the individual level, I think the most basic need of the typical patient is access
to information that is relevant to
his or her individual health profile. This information
must be easy to find and as easy as possible to understand. Patients need a
tool to find their way through the incredible mass of information
they don’t need, or can’t hope to understand, and locate the information they do need and can understand without
specialized training or experience. I
think that ultimately, the most usable tool will be a web-based, user-friendly
data site. It may be part of Medwatch. It may be a clearinghouse for data already online.
It may be an entirely new Web site devoted to this particular purpose. It does
need to be available and usable by ordinary patients trying to make informed decisions about their care.
The patient must also know that the
tool exists. Information about it must
be broadly and consistently distributed through a variety of information portals. These might include television and radio
PSA’s, much like Direct to Consumer advertising, informational
brochures distributed through doctors offices, hospitals, clinics, and
pharmacies, advertisements on patient forums or patient advocacy sites, and
relevant government Web sites. Whatever
the method or methods, the patient population must know about the tool in order
to use it. And if the tool does take the
form of a web-based data access point for patients, there must be an agency or
panel willing to step up and take responsibility for ensuring that the tool is
as accurate, up-to-date, and easy to use as possible.
At the policymaking level, all of
us here today will gain by creating tools that provide more data about what
patients are thinking about their diseases and their treatments. A recent study in Europe
showed that information derived from
online patient forums turned up serious adverse events that had not yet been
reported or detected. With due
consideration for patient privacy in such forums, data mining of this type
could be an extremely valuable tool in assessing post-approval responses to
medications. Polling patient populations
has also uncovered otherwise unrecognized symptoms as basic as pain in
Parkinson’s patients. Finding out what
patients are talking about and thinking in something like real-time is vital to
move quickly in covering and responding to issues that arise after medications
are in the marketplace.
To sum up, we need both the typical
and the atypical patient or patient representative as participants in
healthcare decision-making. Typical patients
will increasingly be called upon to actively participate in the management of
their own health. In turn, the typical
patient needs the atypical patient or patient representative, more familiar
with the intricacies of the health care system and its policymaking apparatus,
to provide the patient perspective on committees, councils, boards -- industrial,
governmental, and academic -- wherever discussions are being held and decisions
made about health care policy and practice. Having the patient involved in the
process of drug trial, approval, labeling, and post-approval monitoring,
provides not only invaluable information
and perspective for health care providers, the drug and biotech industries, and
regulators, but empowers patients, increasing their ability to make informed choices, and provide valuable data, about
their own health care.
Adding the patient perspective to
policymaking will improve those policies. Having the patient perspective at the front
end of the pipeline will result in fewer problems or surprises downstream. By
recognizing and addressing the need for comprehensible, easily accessible information available to all patients, we can make the
average patient a genuine and effective decision-maker in the increasingly
complex world of health care.
|